摘要
目的研究吉西他滨联合卡培他滨治疗耐药转移性乳腺癌的临床疗效及不良反应。方法对2008年6月～2010年3月本院入院治疗的68例乳腺癌患者进行了研究,所有患者在经过紫杉醇、蒽环类药物治疗后均无效果,改用吉西他滨和卡培他滨,第1天和第8天静脉滴注吉西他滨,1g/m2,第1～14天口服卡培他滨,2g/m2,分两次服用,3周为1个治疗周期,至少治疗2个周期,观察临床效果及不良反应。结果 68例患者中,完全缓解12例,占17.6%,部分缓解22例,占32.4%,稳定18例,占26.5%,进展16例,占23.5%,总有效率为50.0%;不良反应主要表现为腹泻、肝功能损伤和手足综合征,均可以耐受。结论吉西他滨联合卡培他滨治疗耐药转移性乳腺癌临床疗效显著,安全性好,不良反应少,值得临床推广应用。
Objective To study the clinical effect of combination chemotherapy of gemcitabine and capecitabine in metastatic breast cancer. Methods Sixty eight cases of patients from June 2008 to March 2010 with metastatic breast cancer were enrolled, all the patients were failed with antracyclines and/or taxanes. Gemcitabine was injected at first and eighth day （1 g/m2）, and capecitabine was oral dose with 2 g/m2 through day 1 to day 14, three weeks were a treatment cycle, and two cycles were needed, clinical effect and side effects were observed. Results Of 68 patients, 12 cases of CR （17.6%）, 22 cases of PR（32.4%）, 18 cases of SD（26.5%） and 16 cases of PD（23.5%）, total effective rate was 50.0%. The main side effects were diarrhea, liver damage and handfoot syndrome, and they were tolerated. Conclusion Combination chemotherapy of gemcitabine and capecitabine shows satisfactory clinical efficacy in the treatment of metastatic breast cancer with tolerated side effect, it was worthy of clinical use.
出处
《中国当代医药》
2012年第7期35-36,共2页
China Modern Medicine
关键词
乳腺癌
吉西他滨
卡培他滨
耐药
Breast cancer
Gemcitabine
Capecitabine
Resistance
